Wiser Advisor Group LLC Has $3.35 Million Stake in Eli Lilly and Company $LLY

Wiser Advisor Group LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,299 shares of the company’s stock after purchasing an additional 77 shares during the period. Eli Lilly and Company makes up approximately 5.8% of Wiser Advisor Group LLC’s portfolio, making the stock its 3rd biggest holding. Wiser Advisor Group LLC’s holdings in Eli Lilly and Company were worth $3,351,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Allianz SE grew its stake in Eli Lilly and Company by 3.3% in the 2nd quarter. Allianz SE now owns 40,499 shares of the company’s stock worth $31,570,000 after buying an additional 1,298 shares in the last quarter. Thompson Davis & CO. Inc. lifted its holdings in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 1,662 shares of the company’s stock worth $1,296,000 after acquiring an additional 60 shares during the last quarter. Good Life Advisors LLC grew its position in Eli Lilly and Company by 5.7% in the second quarter. Good Life Advisors LLC now owns 2,818 shares of the company’s stock worth $2,197,000 after acquiring an additional 153 shares in the last quarter. WASHINGTON TRUST Co grew its position in Eli Lilly and Company by 0.6% in the second quarter. WASHINGTON TRUST Co now owns 18,634 shares of the company’s stock worth $14,526,000 after acquiring an additional 114 shares in the last quarter. Finally, Capital Investment Counsel Inc increased its stake in Eli Lilly and Company by 13.0% in the second quarter. Capital Investment Counsel Inc now owns 771 shares of the company’s stock valued at $601,000 after acquiring an additional 89 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.4%

NYSE:LLY opened at $1,022.00 on Friday. The firm has a market capitalization of $966.19 billion, a P/E ratio of 66.80, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a fifty day moving average of $820.93 and a 200 day moving average of $779.85. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,032.95.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 29.35%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on LLY shares. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Guggenheim restated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, November 3rd. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $999.32.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.